Cargando…

Abl Kinase Regulation by BRAF/ERK and Cooperation with Akt in Melanoma

The melanoma incidence continues to increase, and the disease remains incurable for many due to its metastatic nature and high rate of therapeutic resistance. In particular, melanomas harboring BRAF(V600E) and PTEN mutations often are resistant to current therapies, including BRAF inhibitors (BRAFi)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jain, Aditi, Tripathi, Rakshamani, Turpin, Courtney P., Wang, Chi, Plattner, Rina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552414/ https://www.ncbi.nlm.nih.gov/pubmed/28368422 http://dx.doi.org/10.1038/onc.2017.76

Ejemplares similares

Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1/2-mediated reactivation of MEK/ERK/MYC signaling
por: Tripathi, Rakshamani, et al.
Publicado: (2020)

ABL1/2 and DDR1 Drive MEKi Resistance in NRAS-Mutant Melanomas by Stabilizing RAF/MYC/ETS1 and Promoting RAF Homodimerization
por: Lyon, Anastasia, et al.
Publicado: (2023)

c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression
por: Ganguly, Sourik S., et al.
Publicado: (2011)

ERK5 is activated by oncogenic BRAF and promotes melanoma growth
por: Tusa, Ignazia, et al.
Publicado: (2018)

ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Han, Shujun, et al.
Publicado: (2018)

miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
por: Liu, Szu-Mam, et al.
Publicado: (2014)

AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis
por: McRee, Siobhan K., et al.
Publicado: (2023)

PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells
por: Halaban, Ruth, et al.
Publicado: (2010)

Inhibition of ABL1 by tyrosine kinase inhibitors leads to a downregulation of MLH1 by Hsp70-mediated lysosomal protein degradation
por: Daniels, Hannah G., et al.
Publicado: (2022)

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma
por: Janostiak, Radoslav, et al.
Publicado: (2019)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Publisher Correction: ERK-mediated phosphorylation regulates SOX10 sumoylation and targets expression in mutant BRAF melanoma
por: Han, Shujun, et al.
Publicado: (2018)

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer
por: Ye, Qing, et al.
Publicado: (2013)

Disulfiram/Cu Kills and Sensitizes BRAF-Mutant Thyroid Cancer Cells to BRAF Kinase Inhibitor by ROS-Dependently Relieving Feedback Activation of MAPK/ERK and PI3K/AKT Pathways
por: Xie, Jingyi, et al.
Publicado: (2023)

Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors
por: Sale, Matthew J., et al.
Publicado: (2019)

Intermittent BRAF Inhibition Can Achieve Prolonged Disease Control in BRAF Mutant Melanoma
por: Jain, Tania, et al.
Publicado: (2015)

c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs
por: Xiang, Jinnan, et al.
Publicado: (2017)

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy
por: Paraiso, K H T, et al.
Publicado: (2010)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
por: Jung, Thomas, et al.
Publicado: (2021)

Purinergic calcium signaling drives drug tolerance through ERK reactivation in BRAF-mutant melanoma
por: Stauffer, Philip E., et al.
Publicado: (2023)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
por: Fujimura, Taku, et al.
Publicado: (2019)

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
por: Vergani, Elisabetta, et al.
Publicado: (2022)

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
por: Heidorn, Sonja J., et al.
Publicado: (2010)

Beclin-1–p53 interaction is crucial for cell fate determination in embryonal carcinoma cells
por: Tripathi, Rakshamani, et al.
Publicado: (2014)

T Cell Receptor-Independent Basal Signaling via Erk and Abl Kinases Suppresses RAG Gene Expression
por: Roose, Jeroen P, et al.
Publicado: (2003)

POU4F1 promotes the resistance of melanoma to BRAF inhibitors through MEK/ERK pathway activation and MITF up-regulation
por: Liu, Lin, et al.
Publicado: (2020)

BRAF Mutations and Dysregulation of the MAP Kinase Pathway Associated to Sinonasal Mucosal Melanomas
por: Colombino, Maria, et al.
Publicado: (2019)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2014)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
por: Tan, Yufan, et al.
Publicado: (2021)

Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma
por: Wolfe, Zachary, et al.
Publicado: (2022)

LKB1 loss cooperating with BRAF V600E promotes melanoma cell invasion and migration by up-regulation MMP-2 via PI3K/Akt/mTOR pathway
por: Zhang, Weiming, et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the HSP90 inhibitor AUY922
por: Wang, Chun Yan, et al.
Publicado: (2016)

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
por: Capaldo, Brian J., et al.
Publicado: (2015)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
por: Wong, Deborah JL, et al.
Publicado: (2015)

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway
por: Atefi, Mohammad, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_u17pka1lgnh9avlk9abtu02cue